Esperion Therapeutics (ESPR) Scheduled to Post Quarterly Earnings on Tuesday

Esperion Therapeutics (NASDAQ:ESPR) will be posting its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect Esperion Therapeutics to post earnings of ($0.17) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.03. The business had revenue of $32.25 million during the quarter, compared to analyst estimates of $26.84 million. During the same quarter last year, the business earned ($0.76) earnings per share. On average, analysts expect Esperion Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Esperion Therapeutics Stock Up 1.0 %

Esperion Therapeutics stock opened at $2.08 on Monday. Esperion Therapeutics has a 1-year low of $0.70 and a 1-year high of $3.40. The company has a fifty day simple moving average of $2.34 and a 200 day simple moving average of $2.05.

Wall Street Analyst Weigh In

ESPR has been the subject of several analyst reports. Needham & Company LLC restated a “buy” rating and issued a $8.00 price objective on shares of Esperion Therapeutics in a report on Wednesday, April 10th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Monday, March 25th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $9.33.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.